Primary signet ring cell carcinoma of the pancreatic head: A case report

Pancreatic SRCC is a rare, aggressive tumor. Given limited evidence and the risk of side effects, physicians may elect to withhold chemotherapy in select patients, with the exception of neoadjuvant chemotherapy use to facilitate resectability. Pancreatic SRCC is a rare, aggressive tumor. Given limit...

Full description

Saved in:
Bibliographic Details
Published inClinical case reports Vol. 7; no. 11; pp. 2235 - 2238
Main Authors Alexander, Dheeraj, Rashid, Lewis, Hollis, Michael, Kavuturu, Srinivas
Format Journal Article
LanguageEnglish
Published Bognor Regis John Wiley & Sons, Inc 01.11.2019
John Wiley and Sons Inc
Wiley
Subjects
Abdomen
Case Report
Case Reports
Chemotherapy
Endoscopy
Histology
Literature reviews
Medical imaging
Metastasis
Morphology
Pancreas
Pancreatic cancer
pancreaticoduodenectomy
Signet ring cell carcinoma
Online AccessGet full text

Cover

More Information
Summary:Pancreatic SRCC is a rare, aggressive tumor. Given limited evidence and the risk of side effects, physicians may elect to withhold chemotherapy in select patients, with the exception of neoadjuvant chemotherapy use to facilitate resectability. Pancreatic SRCC is a rare, aggressive tumor. Given limited evidence and the risk of side effects, physicians may elect to withhold chemotherapy in select patients, with the exception of neoadjuvant chemotherapy use to facilitate resectability.
ISSN:2050-0904
2050-0904
DOI:10.1002/ccr3.2475